Peroxisome proliferator-activated receptor-γ agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control

Endocrine Practice

Volumn 9, Issue 6, 2003, Pages 487-493

  Bavirti, Surekha ^a   Ghanaat, Farhad ^a   Tayek, John A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CELL RECEPTOR; CHROMAN DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRANSCRIPTION FACTOR; TROGLITAZONE; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; BLOOD; CLINICAL TRIAL; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE;

BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHROMANS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; PARTICLE SIZE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 1442285918     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.9.6.487     Document Type: Article

References (24)

1. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapo B: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135:447-459.
2. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism. 2002;51:334-342.
3. O'Neal DN, O'Brien RC, Timmins KL, et al. Gemfibrozil treatment increases low-density lipoprotein particle size in type 2 diabetes mellitus but does not alter in vitro oxidizability. Diabet Med. 1998;15:870-877.
4. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis. 2002;160:41-48.
5. Cominacini L, Young MM, Capriati A, et al. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia. 1997;40:1211-1218.
6. Tack CJ, Smits P, Demacker PN, Stalenhoef AF. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care. 1998;21:796-799.
7. Okumura K, Matsui H, Kawakami K, et al. Low density lipoprotein particle size is associated with glycosylated hemoglobin levels regardless of plasma lipid levels. Intern Med. 1998;37:273-279.
8. Shirai K, Itoh Y, Sasaki H, et al. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract. 1999;46:35-41.
9. Caixas A, Ordonez-Llanos J, de Leiva A, Payes A, Homs R, Perez A. Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes. 1997;46: 1207-1213.
10. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
11. Sunayama S, Watanabe Y, Ohmura H, et al. Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis. 1999;146:187-193.
12. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes [erratum in Diabetes Care. 2002;25:947]. Diabetes Care. 2002;25:542-549.
13. Sampson MJ, Astley S, Richardson T, et al. Increased DNA oxidative susceptibility without increased plasma LDL oxidizability in type II diabetes: effects of alpha-tocopherol supplementation. Clin Sci (Lond). 2001;101:235-241.
14. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 2001;88:270-274.
15. Freed MI, Ratner R, Marcovina SM, et al (Rosiglitazone Study 108 Investigators). Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 2002;90:947-952.
16. Ovalle F, Bell DSH. Effect of thiazolidinediones on highdensity lipoprotein subfractions. Endocr Pract. 2002;8:102-104.
17. Gokkusu C, Palanduz S, Ademoglu E, Tamer S. Oxidant and antioxidant systems in NIDDM patients: influence of vitamin E supplementation. Endocr Res. 2001;27:377-386.
18. Cloarec MJ, Perdriset GM, Lamberdiere FA, et al. Alpha-tocopherol: effect on plasma lipoproteins in hypercholesterolemic patients. Isr J Med Sci. 1987;23:869-872.
19. Schnell JW, Anderson RA, Stegner JE, Schindler SP, Weinberg RB. Effects of a high polyunsaturated fat diet and vitamin E supplementation on high-density lipoprotein oxidation in humans. Atherosclerosis. 2001;159:459-466.
20. Stampfer MJ,Willett W, Castelli WP, Taylor JO, Fine J, Hennekens CH. Effect of vitamin E on lipids. Am J Clin Pathol. 1983;79:714-716.
21. Arrol S, Mackness MI, Durrington PN. Vitamin E supplementation increases the resistance of both LDL and HDL to oxidation and increases cholesteryl ester transfer activity. Atherosclerosis. 2000;150:129-134.
22. Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. 2001;286:1468-1474.
23. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347:1483-1492.
24. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453-462.